Company Description
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial.
The company was incorporated in 1998 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 352 |
| CEO | Dr. Joseph K. Belanoff M.D. |
Contact Details
Address: 149 Commonwealth Drive Menlo Park, California 94025 United States | |
| Phone | 650.688.8803 |
| Website | corcept.com |
Stock Details
| Ticker Symbol | CORT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001088856 |
| CUSIP Number | 218352102 |
| ISIN Number | US2183521028 |
| Employer ID | 77-0487658 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, Chief Executive Officer and Director |
| Atabak Mokari | Chief Financial Officer and Treasurer |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer |
| Sean Maduck | President of Endocrinology |
| Gary Charles Robb | Chief Business Officer and Secretary |
| Joseph Douglas Lyon | Chief Accounting and Technology Officer |
| Amy Flood | Chief Human Resources and Communications Officer |
| Dr. William Guyer Pharm.D. | Chief Development Officer |
| Monica Tellado | President of Emerging Markets |
| Roberto W. Vieira | President of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2024 | ARS | Filing |
| Apr 17, 2024 | 8-K | Current Report |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |
| Mar 27, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 27, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Feb 16, 2024 | 144 | Filing |